Keywords

Spleen Polypeptide Injection Transcatheter Arterial Chemoembolization Liver Neoplasms Treatment Outcome

Abstract

Objective To explore the clinical efficacy of spleen polypeptide injection combined with transcatheter hepatic arterial chemoembolization (TACE) in the treatment of intermediate and advanced primary liver cancer. Methods 60 patients with intermediate and advanced primary liver cancer who were treated in our hospital from June 2013 to January 2015 were selected and randomly divided into the spleen polypeptide group (splen polypeptide injection combined with TACE) and the control group (TACE alone). group of 30 patients. Evaluate and compare the quality of life (KPS score), immune function, and clinical efficacy (RECIST 1.1 standard), KPS score, and immune function one month after treatment between the two groups of patients before treatment. Record and compare the incidence of adverse reactions between the two groups of patients. and survival rate. Results The objective effective rate (complete remission + partial remission) of the spleen polypeptide group was 63.3% (19/30), and that of the control group was 33.3% (10/30). The difference between the two groups was statistically significant (P<0.05). The KPS of patients in the spleen peptide group improved significantly after treatment compared with the control group, and the difference between the two groups was statistically significant (P<0.05). The CD3+, CD4+, and CD4+/CD8+ ratios in the spleen peptide group were higher after treatment than before treatment (P<0.05), while the immunological indicators in the control group had no significant changes before and after treatment. The incidence of adverse reactions such as blood toxicity and gastrointestinal reactions in the spleen peptide group was lower than that in the control group (P<0.05). The 1-year survival rates of the spleen polypeptide group and the control group were 53.3% and 43.3% respectively, with no statistically significant difference (P>0.05). The 2-year survival rate of patients in the spleen polypeptide group was 40.0%, which was higher than the 13.3% of the control group. , the difference is statistically significant (P<0.05). Conclusion Spleen polypeptide injection combined with TACE can improve the clinical efficacy of patients with intermediate and advanced primary liver cancer, prolong their survival, improve their quality of life, and increase their immune function. Objective To explore the clinical efficacy of lienal polypeptide injection combined with transcatheter arterial chemoembolization (TACE) for treatment of patients with advanced primary liver cancer. Methods A total of 60 patients with advanced primary liver cancer were enrolled from Jun. 2013 to Jan. 2015 in Eastern Hepatobiliary Surgery Hospital, and were divided randomly into treatment group (lienal polypeptide injection combined with TACE, n=30) and control group (TACE, n=30). We observed the quality of life (KPS score) and immunity index of the patients in two groups before treatment and observed the clinical efficacy (RECIST 1.1 criteria), KPS score and immunity index after treatment for one month, then and recorded and compared the adverse effects and survival rates in two groups. Results The objective effective rate (complete remission and partial remission) was 63.3% (19/30) in treatment group and was 33.3% (10/30) in control group, with significant difference between the two groups (P<0.05). The KPS score of treatment group was better than that of control group (P<0.05). In treatment group, the CD3+ and CD4+ lymphocytes and the ratio of CD4+ to CD8+ lymphocytes were significantly increased after the treatment (P<0.05), and they had no significant change in control group before and after treatment. The incidences of adverse reactions, such as hematological toxicity and gastrointestinal reactions in treatment group were significantly lower than those in the control group (P<0.05). There was no significant difference in one-year survival rate between treatment group ( 53.3%) and control group (43.3%, P>0.05), while the two-year survival rate of treatment group was significantly higher than that in the control group (40.0% vs 13.3%, P<0.05). Conclusion Lienal polypeptide injection combined with TACE can improve the clinical efficacy and survival rate of the patients with advanced primary liver cancer   For further details regarding this article and its research, please do not hesitate to contact our team for assistance. Original research done by Zhou Fuping, Yang Xijing, Wang Zhen, Zhang Qian  

About ETprotein

ETprotein, a reputable plant protein vegan protein Chinese factory manufacturer and supplier, is renowned for producing, stocking, exporting, and delivering the highest quality organic bulk vegan protein and plant proteins. They include Organic rice protein, clear rice protein, pea protein, clear pea protein, watermelon seed protein, pumpkin seed protein, sunflower seed protein, mung bean protein, peanut protein etc. Their offerings, characterized by a neutral taste, non-GMO, allergen-free attributes, cater to a diverse range of industries. They serve nutraceutical, pharmaceutical, cosmeceutical, veterinary, as well as food and beverage finished product distributors, traders, and manufacturers across Europe, USA, Canada, Australia, Thailand, Japan, Korea, Brazil, and Chile, among others.

ETprotein specialization includes exporting and delivering tailor-made protein powder and finished nutritional supplements. Their extensive product range covers sectors like Food and Beverage, Sports Nutrition, Weight Management, Dietary Supplements, Health and Wellness Products, and Infant Formula, ensuring comprehensive solutions to meet all your protein needs.

As a trusted company by leading global food and beverage brands and Fortune 500 companies, ETprotein reinforces China’s reputation in the global arena. For more information or to sample their products, please contact them and email sales(at)ETprotein.com today.

Featured Products on Sale

Organic Brown Rice Protein

Protein: 80%, 85%,90%
NON-GMO, Solvents-free, Soy-free, Gluten-free, Low sodium, Low heavy metals, Pesticides free
Neutral taste, Lower fat, Longer shelf life
Organic COI/TC certificate is available for the European market
NOP import certificate is available for the USA/Canada market
Competitive price

Clear Rice Protein(Hydrolyzed Rice Protein)

Protein Min 85%
Neutral taste, win over all over the world’s existing competitors
Instant solubility in water, generates a clear solution, no sediments, and Stable for a longer shelflife

Pea Protein

Protein: 80%, 85%,90%
Neutral taste, Non-GMO, Solvents free, Soy-free, Gluten-free, Vegan, Low sodium,Lower heavy metals
Types for vegan meat, vegan beverage
Competitive price

Clear Pea Protein(Hydrolyzed Pea Protein)

Protein Min 85%
Neutral taste, win over all over the world’s existing competitors
Non-GMO, Solvents free, Soy-free, Gluten-free, Vegan, Low sodium, Lower heavy metals
Instant solubility in water, generates clear solution, no sediments, Stable for longer shelflife

Organic Pumpkin Seed Protein

Protein Min 70%
Neutral typical smooth taste, win over all over other existing competitors
NOP import certificate is available for the USA/Canada market

Contact sales@etprotein.com for a quotation and Free samples.

We’re excited to provide you with top-notch proteins and great customer service!